Advanced Enzyme Technologies Limited (NSE:ADVENZYMES)
India · Delayed Price · Currency is INR | Market Cap | 31.25B -10.1% |
| Revenue (ttm) | 7.82B +10.6% |
| Net Income | 1.71B +15.9% |
| EPS | 15.25 +15.9% |
| Shares Out | 111.15M |
| PE Ratio | 18.44 |
| Forward PE | n/a |
| Dividend | 5.35 (1.90%) |
| Ex-Dividend Date | Jul 24, 2026 |
| Volume | 303,708 |
| Open | 284.75 |
| Previous Close | 284.20 |
| Day's Range | 278.95 - 284.75 |
| 52-Week Range | 246.80 - 419.00 |
| Beta | 0.67 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 3, 2026 |
About NSE:ADVENZYMES
Advanced Enzyme Technologies Limited, together with its subsidiaries, engages in the research, development, manufacture, and marketing of enzymes and probiotics in India, Europe, the United States, Asia, and internationally. The company offers serratiopeptidase, fungal lactase, peptizyme SP, nattokinase, fungal lipase, alpha galactosidase, saccharomyces boulardii, hemicellulose, papain, bromelain, fungal proteases, and bacterial alpha amylase. It also provides probiotics for human and animal nutrition. In addition, the company offers enzymes an... [Read more]
Financial Performance
In fiscal year 2026, NSE:ADVENZYMES's revenue was 7.46 billion, an increase of 17.09% compared to the previous year's 6.37 billion. Earnings were 1.69 billion, an increase of 28.68%.
Financial StatementsNews
Advanced Enzyme Technologies Transcript: Q2 26/27
Q2 revenue grew 16% YoY and EBITDA 20%, with growth across segments and a 34% EBITDA margin. Management targets lower-to-mid double-digit growth and a 30%-32% overall EBITDA margin, while the U.S. recovery remains uncertain.
Advanced Enzyme Technologies Slides: Q2 2027
Advanced Enzyme Technologies has posted slides in relation to its Q2 2027 quarterly earnings report, which was published on November 3, 2026.
Advanced Enzyme Technologies Quarterly report: Q2 2027
Advanced Enzyme Technologies has published its Q2 2027 quarterly earnings report on November 3, 2026.
Advanced Enzyme Technologies Transcript: Q1 26/27
Q1 FY27 revenue grew 2% year-on-year but declined sequentially due to sales reversals and cost pressures, with EBITDA margin at 27%. Management expects double-digit annual growth and margin recovery, supported by robust R&D investment and a buyback initiative.
Advanced Enzyme Technologies Quarterly report: Q1 2027
Advanced Enzyme Technologies has published its Q1 2027 quarterly earnings report on August 12, 2026.
Advanced Enzyme Technologies Slides: Q1 2027
Advanced Enzyme Technologies has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on August 12, 2026.
Advanced Enzyme Technologies Transcript: Q4 25/26
Record revenue and profit growth achieved in FY 2026, with strong performance across all segments and geographies. Margin stability is expected despite inflation and global uncertainties, supported by R&D investments and capacity expansion.
Advanced Enzyme Technologies Quarterly report: Q4 2026
Advanced Enzyme Technologies has published its Q4 2026 quarterly earnings report on May 11, 2026.
Advanced Enzyme Technologies Slides: Q4 2026
Advanced Enzyme Technologies has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 11, 2026.
Advanced Enzyme Technologies Annual report: Q4 2026
Advanced Enzyme Technologies has published its Q4 2026 annual report on May 11, 2026.
Advanced Enzyme Technologies shares surge 12.25% to ₹401 as FY26 profit jumps 29.6% to ₹173.6 crore
Shares of Advanced Enzyme Technologies Limited emerged as one of the top gainers on the NSE on May 11, surging 12.25% or ₹43.75 to ₹401 in early trade, touching an…
Advanced Enzyme Technologies announces resignation of senior vice president
Advanced Enzyme Technologies has announced the resignation of Mr. Dipak Roda, Senior Vice President - Marketing and Business Development. His resignation will be effective from the close of business h...
Advanced Enzyme Technologies Transcript: Q3 25/26
Q3 revenue grew 2% year-over-year but declined sequentially, with strong nine-month growth of 15%. Human Healthcare faced headwinds, while Animal Healthcare and Bioprocessing segments delivered robust gains. Management expects double-digit growth ahead, supported by new R&D initiatives.
Advanced Enzyme Technologies Quarterly report: Q3 2026
Advanced Enzyme Technologies has published its Q3 2026 quarterly earnings report on February 4, 2026.
Advanced Enzyme Technologies Slides: Q3 2026
Advanced Enzyme Technologies has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on February 4, 2026.
Advanced Enzyme Technologies Transcript: Q2 25/26
Q2 FY26 saw 26% YoY revenue growth and 42% YoY EBITDA growth, with strong performance across all segments and a 33% EBITDA margin. U.S. tariffs impacted American sales, but management maintains mid-double-digit growth guidance and plans increased R&D investment as a new center comes online.
Advanced Enzyme Technologies Quarterly report: Q2 2026
Advanced Enzyme Technologies has published its Q2 2026 quarterly earnings report on November 13, 2025.
Advanced Enzyme Technologies Slides: Q2 2026
Advanced Enzyme Technologies has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on November 13, 2025.
Advanced Enzyme shares jump 9% today after Q2 profit rises 32% YoY to Rs 43.3 crore
Shares of Advanced Enzyme Technologies Ltd. surged as much as 9% on Wednesday, November 12, after the company announced its...